Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors
A Clinical Trial of Non-cationic Peptide-CD47 siRNA for Safety, Tolerability, and Preliminary Antitumor Activity in Patients With Advanced Malignant Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients aged ≥18 years and ≤70 years.
- Histopathologically confirmed advanced recurrent/metastatic malignant solid tumors that are refractory to second-line treatment and have no available standard clinical therapeutic options (e.g., advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.).
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
- Expected overall survival ≥3 months.
- Interval from the last chemotherapy, radiotherapy, or surgery ≥28 days.
- Interval from the last use of nitrosourea or mitomycin C ≥6 weeks.
- Adequate organ function, defined by the following laboratory parameters within 14 days prior to enrollment:
- Hemoglobin ≥90 g/L (no blood transfusion within 14 days).
- Absolute neutrophil count >1.5 × 10⁹/L.
- Platelet count ≥80 × 10⁹/L.
- Total bilirubin ≤1.5 × upper limit of normal (ULN).
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN in case of liver metastasis).
- Creatinine clearance ≥60 mL/min (calculated by Cockcroft-Gault formula).
- Left ventricular ejection fraction (LVEF) ≥50%.
- Signed written informed consent.
Exclusion Criteria:
- Participation in another investigational drug clinical trial within 4 weeks.
- Tumor located adjacent to major blood vessels or trachea.
- Uncontrolled cardiac clinical symptoms or diseases, including New York Heart -Association (NYHA) Class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular/ventricular arrhythmias requiring treatment or intervention.
- Female patients who are pregnant or lactating.
- Active pulmonary tuberculosis, bacterial or fungal infection (≥Grade 2 per NCI-CTCAE version 5.0), active human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection.
- History of uncontrollable psychoactive substance abuse or presence of mental disorders.
- Any active autoimmune disease or history of autoimmune disease, including but not limited to uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism. Subjects with vitiligo or childhood asthma in complete remission (no adult intervention required) are eligible; subjects with asthma requiring bronchodilator therapy are excluded.
- Receiving immunosuppressive therapy.
- History of drug abuse or known medical, psychological, or social conditions that interfere with study compliance (e.g., alcoholism or illicit drug addiction).
- Known hypersensitivity, allergy, or intolerance to the study drug NCP-CD47 siRNA (including any excipients), or history of severe allergic reactions to any drugs, foods, or vaccines (e.g., anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local Arthus reaction, etc.).
- Female subjects planning pregnancy, or male subjects whose partner plans pregnancy, from screening until 12 months after the last study drug injection.
- Any concomitant disease that, in the investigator's judgment, may seriously compromise patient safety or prevent the subject from completing the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intratumoral NCP-CD47 siRNA injection group
|
NCP-CD47 siRNA will be administered via intratumoral injection.
A total of 5 doses will be given, with subsequent doses administered once weekly after the first injection.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Time Frame: From the first dose to the end of treatment at 9 weeks
|
DLT is defined as any Treatment-Related Adverse Event (TRAE) or clinically significant laboratory abnormality occurring during the DLT observation period.
TRAEs include events judged by the investigator to be "definitely," "probably," or "possibly" related to the study treatment.
Severity will be graded according to NCI-CTCAE v5.0.
|
From the first dose to the end of treatment at 9 weeks
|
|
Number of participants with treatment discontinuation due to treatment-related adverse events during the first treatment cycle
Time Frame: From the first dose to the end of treatment at 9 weeks
|
Treatment-related adverse events (TRAEs) will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Treatment discontinuation is defined as permanent cessation of NCP-CD47 siRNA administration due to investigator-determined TRAEs occurring during the first treatment cycle.
|
From the first dose to the end of treatment at 9 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-Free Survival
Time Frame: Up to 6 months from the date of the first dose.
|
Progression-Free Survival (PFS) is defined as the time interval from the start of treatment until the first documented occurrence of disease progression (PD) according to RECIST v1.1, or death due to any cause, whichever occurs first.
|
Up to 6 months from the date of the first dose.
|
|
Overall Survival
Time Frame: Up to 12 months from the date of the first dose.
|
OS is defined as the time interval from the start of treatment to death due to any cause.
For participants who are still alive at the end of the study, data will be censored at the last known date of follow-up.
|
Up to 12 months from the date of the first dose.
|
|
Objective Response
Time Frame: Time Frame: Up to 6 months from the date of the first dose.
|
Number of participants achieving a Best Overall Response (BOR) of either Complete Response (CR) or Partial Response (PR) according to RECIST v1.1.
Due to the small sample size, data will be reported as absolute counts.
|
Time Frame: Up to 6 months from the date of the first dose.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-892
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.